The SEC is looking into whether generic-drug maker Mylan (MYL) improperly disclosed confidential earnings data to several analysts and investors in a Sept. 2009 meeting, prompting a 7% rise in its stock the next day on three times as much volume as usual.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.